Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00699374
First received: June 16, 2008
Last updated: December 7, 2012
Last verified: December 2012
  Purpose

The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.


Condition Intervention Phase
Carcinoma, Hepatocellular
Drug: sunitinib malate
Drug: sorafenib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150 ] [ Designated as safety issue: No ]
    Overall survival is the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.


Secondary Outcome Measures:
  • Progression-Free Survival (PFS) [ Time Frame: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150 ] [ Designated as safety issue: No ]
    The period from randomization until disease progression or death.

  • Time to Tumor Progression (TTP) [ Time Frame: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150 ] [ Designated as safety issue: No ]
    Time in weeks from randomization to first documentation of objective tumor progression or death due to cancer, whichever comes first. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])

  • European Quality of Life (EQ-5D)- Health State Profile Utility Score [ Time Frame: Day 1 of each cycle ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula assigns a utility value for each domain in the profile. Score is transformed and results in a score range -0.594 to 1.000; higher score indicates better health state.


Enrollment: 1075
Study Start Date: July 2008
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
sunitinib arm
Drug: sunitinib malate
sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
Other Name: Sutent®
Active Comparator: Arm B
sorafenib arm
Drug: sorafenib
sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
Other Name: Nexavar®

Detailed Description:

This study was terminated on April 22th, 2010, based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm, and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer. Patients on sunitinib who are judged by the investigator as receiving clinical benefit may chose to remain on study and continue treatment with sunitinib until clinical benefit as per the investigator's judgment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically-confirmed diagnosis of hepatocellular carcinoma
  • presence of measurable disease by radiographic imaging
  • Child-Pugh class A
  • ECOG PS 0 or 1
  • adequate organ function.

Exclusion Criteria:

  • Prior treatment with any systemic treatment for hepatocellular carcinoma
  • prior local treatment within 4 weeks from entry
  • presence of clinically relevant ascites
  • severe hemorrhage <4 weeks of starting study treatment
  • known HIV or serious acute or chronic illness
  • current treatment on another clinical trial
  • pregnancy or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00699374

  Hide Study Locations
Locations
United States, California
Pfizer Investigational Site
Fountain Valley, California, United States, 92708
Pfizer Investigational Site
La Jolla, California, United States, 92093
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
Orange, California, United States, 92868
Pfizer Investigational Site
San Diego, California, United States, 92103
United States, Florida
Pfizer Investigational Site
Miami, Florida, United States, 33136
United States, Georgia
Pfizer Investigational Site
Ringgold, Georgia, United States, 30736
United States, Iowa
Pfizer Investigational Site
Iowa City, Iowa, United States, 52242
United States, Kentucky
Pfizer Investigational Site
Crestview Hills, Kentucky, United States, 41017
United States, New York
Pfizer Investigational Site
Bronx, New York, United States, 10467
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45242
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45236
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45238
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45248
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45230
Pfizer Investigational Site
Fairfield, Ohio, United States, 45014
Pfizer Investigational Site
Hamilton, Ohio, United States, 45013
United States, Tennessee
Pfizer Investigational Site
Chattanooga, Tennessee, United States, 37404
Pfizer Investigational Site
Franklin, Tennessee, United States, 37067
Pfizer Investigational Site
Gallatin, Tennessee, United States, 37066
Pfizer Investigational Site
Hermitage, Tennessee, United States, 37076
Pfizer Investigational Site
Hixson, Tennessee, United States, 37343
Pfizer Investigational Site
Lebanon, Tennessee, United States, 37087
Pfizer Investigational Site
Murfreesboro, Tennessee, United States, 37130
Pfizer Investigational Site
Nashville, Tennessee, United States, 37207
Pfizer Investigational Site
Nashville, Tennessee, United States, 37205
Pfizer Investigational Site
Nashville, Tennessee, United States, 37211
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
Pfizer Investigational Site
Smyrna, Tennessee, United States, 37167
United States, Virginia
Pfizer Investigational Site
Mechanicsville, Virginia, United States, 23116
Pfizer Investigational Site
Midlothian, Virginia, United States, 23114
Pfizer Investigational Site
Richmond, Virginia, United States, 23235-4730
Pfizer Investigational Site
Richmond, Virginia, United States, 23230
United States, Washington
Pfizer Investigational Site
Seattle, Washington, United States, 98101
Australia, New South Wales
Pfizer Investigational Site
Concord, New South Wales, Australia, 2139
Australia, South Australia
Pfizer Investigational Site
Elizabeth Vale, South Australia, Australia, 5112
Pfizer Investigational Site
Woodville South, South Australia, Australia, 5011
Australia, Victoria
Pfizer Investigational Site
Melbourne, Victoria, Australia, 3004
Pfizer Investigational Site
Parkville, Victoria, Australia, 3050
Belgium
Pfizer Investigational Site
Bruxelles, Belgium, 1070
Pfizer Investigational Site
Bruxelles, Belgium, 1200
Pfizer Investigational Site
Gent, Belgium, 900
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada, T2N 4N2
Canada, British Columbia
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Pfizer Investigational Site
Kingston, Ontario, Canada, K7L 5P9
Pfizer Investigational Site
Toronto, Ontario, Canada, M6R 1B5
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H2X 3J4
China, Anhui
Pfizer Investigational Site
Hefei, Anhui, China, 230022
China, Fujian
Pfizer Investigational Site
Fuzhou City, Fujian, China, 350014
China, Guangdong
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510080
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510060
China, Guangxi
Pfizer Investigational Site
Nanning, Guangxi, China, 530021
China, Hubei
Pfizer Investigational Site
Wuhan, Hubei, China, 430030
China, Jiangsu
Pfizer Investigational Site
Nanjing, Jiangsu, China, 210002
China, Sichuan
Pfizer Investigational Site
Chengdu, Sichuan, China, 610041
China, Zhejiang
Pfizer Investigational Site
Hangzhou, Zhejiang, China, 310022
Pfizer Investigational Site
Hangzhou, Zhejiang, China, 310016
China
Pfizer Investigational Site
Beijing, China, 100071
Pfizer Investigational Site
Beijing, China, 100035
Pfizer Investigational Site
Bejing, China, 100021
Pfizer Investigational Site
Chong qing, China, 400038
Pfizer Investigational Site
Guangzhou, China, 510515
Pfizer Investigational Site
Nanjing, China, 210009
Pfizer Investigational Site
Shanghai, China, 200070
France
Pfizer Investigational Site
Amiens Cedex 1, France, 80054
Pfizer Investigational Site
Bordeaux Cedex, France, 33075
Pfizer Investigational Site
Clichy Cedex, France, 92118
Pfizer Investigational Site
Creteil Cedex, France, 94010
Pfizer Investigational Site
Lille Cedex, France, 59037
Pfizer Investigational Site
Nice Cedex 2, France, 06189
Pfizer Investigational Site
Paris, France, 75012
Pfizer Investigational Site
Paris Cedex 13, France, 75651
Pfizer Investigational Site
St Herblain Cedex, France, 44805
Pfizer Investigational Site
Strasbourg Cedex, France, 67091
Pfizer Investigational Site
Toulouse, France, 31059
Pfizer Investigational Site
Vandoeuvre Les Nancy Cedex, France, 54511
Pfizer Investigational Site
Villejuif Cedex, France, 94804
Germany
Pfizer Investigational Site
Hamburg, Germany, 20246
Pfizer Investigational Site
Hannover, Germany, 30625
Pfizer Investigational Site
Mainz, Germany, 55131
Pfizer Investigational Site
Muenchen, Germany, 81377
Hong Kong
Pfizer Investigational Site
Hong Hong, Hong Kong
Pfizer Investigational Site
Kowloon, Hong Kong
Pfizer Investigational Site
Shatin, New Territories, Hong Kong
Pfizer Investigational Site
Tuen Mun, New Territories, Hong Kong
Italy
Pfizer Investigational Site
Meldola, FC, Italy, 47014
Pfizer Investigational Site
Bari, Italy, 70126
Pfizer Investigational Site
Bologna, Italy, 40138
Pfizer Investigational Site
Cattolica (RN), Italy, 47841
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Milano, Italy, 20122
Pfizer Investigational Site
Padova, Italy, 35128
Pfizer Investigational Site
Pavia, Italy, 27100
Pfizer Investigational Site
Ravenna, Italy, 48100
Pfizer Investigational Site
Rimini, Italy, 47900
Japan
Pfizer Investigational Site
Nagoya, Aichi, Japan
Pfizer Investigational Site
Chiba city, Chiba, Japan
Pfizer Investigational Site
Kashiwa-shi, Chiba, Japan
Pfizer Investigational Site
Kurume city, Fukuoka, Japan
Pfizer Investigational Site
Gifu-shi, Gifu, Japan
Pfizer Investigational Site
Sapporo-shi, Hokkaido, Japan
Pfizer Investigational Site
Nishinomiya, Hyogo, Japan
Pfizer Investigational Site
Kanazawa city, Ishikawa, Japan
Pfizer Investigational Site
Omura-shi, Nagasaki, Japan
Pfizer Investigational Site
Osaka-shi, Osaka-fu, Japan
Pfizer Investigational Site
Osaka-Sayama, Osaka, Japan
Pfizer Investigational Site
Izunokuni-shi, Shizuoka, Japan
Pfizer Investigational Site
Bunkyo-ku, Tokyo, Japan
Pfizer Investigational Site
Chiyoda-ku, Tokyo, Japan
Pfizer Investigational Site
Chuo-ku, Tokyo, Japan
Pfizer Investigational Site
Itabashi-ku, Tokyo, Japan
Pfizer Investigational Site
Mitaka-shi, Tokyo, Japan
Pfizer Investigational Site
Setagaya-ku, Tokyo, Japan
Pfizer Investigational Site
Okayama, Japan
Korea, Republic of
Pfizer Investigational Site
Chonju, Chonbuk, Korea, Republic of, 561-712
Pfizer Investigational Site
Goyang-si, Gyeonggi-do, Korea, Republic of, 411-769
Pfizer Investigational Site
Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-809
Pfizer Investigational Site
Busan, Korea, Republic of, 614-735
Pfizer Investigational Site
Daegu, Korea, Republic of, 705-718
Pfizer Investigational Site
Daegu, Korea, Republic of, 700-712
Pfizer Investigational Site
Incheon, Korea, Republic of, 405-760
Pfizer Investigational Site
Seoul, Korea, Republic of, 138-736
Pfizer Investigational Site
Seoul, Korea, Republic of, 120-752
Pfizer Investigational Site
Seoul, Korea, Republic of, 152-703
Pfizer Investigational Site
Seoul, Korea, Republic of, 110-744
Pfizer Investigational Site
Seoul, Korea, Republic of, 135-710
Malaysia
Pfizer Investigational Site
Lembah Pantai, Kuala Lumpur, Malaysia, 59100
Pfizer Investigational Site
Subang Jaya, Selangor, Malaysia, 47500
Pfizer Investigational Site
Kuala Lumpur, Malaysia, 50586
Philippines
Pfizer Investigational Site
Cebu City, Cebu, Philippines, 6000
Pfizer Investigational Site
Cebu City, Philippines, 6000
Pfizer Investigational Site
Davao City, Philippines
Pfizer Investigational Site
Manila, Philippines, 1015
Pfizer Investigational Site
Manila, Philippines, 1000
Pfizer Investigational Site
Quezon City, Philippines, 1104
Pfizer Investigational Site
Quezon City, Philippines
Pfizer Investigational Site
Quezon City, Philippines, 1102
Poland
Pfizer Investigational Site
Warszawa, Poland, 02-781
Pfizer Investigational Site
Warszawa, Poland, 02-097
Russian Federation
Pfizer Investigational Site
Chelyabinsk, Russian Federation, 454087
Pfizer Investigational Site
Pyatigorsk, Russian Federation, 357502
Pfizer Investigational Site
St.Petersburg, Russian Federation, 194044
Singapore
Pfizer Investigational Site
Singapore, Singapore, 169610
Pfizer Investigational Site
Singapore, Singapore, 119074
South Africa
Pfizer Investigational Site
Parktown, South Africa, 2193
Spain
Pfizer Investigational Site
Sabadell, Barcelona, Spain, 08208
Pfizer Investigational Site
Santander, Cantabria, Spain, 39008
Pfizer Investigational Site
Palma de Mallorca, Illes Balears, Spain, 07198
Pfizer Investigational Site
El Palmar, Murcia, Spain, 30120
Pfizer Investigational Site
Sevilla, Spain, 41013
Sweden
Pfizer Investigational Site
Linkoping, Sweden, 581 85
Taiwan
Pfizer Investigational Site
Pu-Tz City, Chai-Yi, Taiwan, 613
Pfizer Investigational Site
Kwei-Shan, Taoyuan, Taiwan, 333
Pfizer Investigational Site
Changhua, Taiwan, 500
Pfizer Investigational Site
Kaohsiung, Taiwan, 807
Pfizer Investigational Site
Kaohsiung, Taiwan, 833
Pfizer Investigational Site
Taichung, Taiwan, 404
Pfizer Investigational Site
Taichung City, Taiwan, 407
Pfizer Investigational Site
Tainan, Taiwan, 704
Pfizer Investigational Site
Tainan, Taiwan, 736
Pfizer Investigational Site
Taipei, Taiwan, 110
Pfizer Investigational Site
Taipei, Taiwan, 112
Thailand
Pfizer Investigational Site
Bangkok Noi, Bangkok, Thailand, 10700
Pfizer Investigational Site
Ptumwan, Bangkok, Thailand, 10330
Pfizer Investigational Site
Amphoe Mueang, Chiang Mai, Thailand, 50200
Turkey
Pfizer Investigational Site
Ankara, Turkey, 06100
Pfizer Investigational Site
Istanbul, Turkey
United Kingdom
Pfizer Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CR2 0QQ
Pfizer Investigational Site
London, United Kingdom, W12 OHS
Pfizer Investigational Site
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00699374     History of Changes
Other Study ID Numbers: A6181170
Study First Received: June 16, 2008
Results First Received: December 7, 2012
Last Updated: December 7, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
sunitinib
phase 3
randomized
hepatocellular
liver

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Sorafenib
Sunitinib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on July 20, 2014